Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

439
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
439
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

248
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Risk of colorectal cancer by socioeconomic position and history of mental illness - a national nested case-control study.

BMC cancer·2026
Same author

Prevalence of self-reported pain in patients 5 years after rectal cancer treatment: results from the prospective QoLiRECT cohort study.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers.

Molecular cancer·2026
Same author

Polarization of tumor-infiltrating macrophages predicts complete response to neoadjuvant treatment in patients with rectal cancer.

Oncoimmunology·2026
Same author

Reconsidering functional outcomes in watch-and-wait rectal cancer after total neoadjuvant treatment.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Validation of the reporting of local recurrence of rectal cancer in the Swedish ColoRectal Cancer Registry (SCRCR).

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2026

相关实验视频

Updated: Jan 17, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.4K

低剂量阿司匹林用于PI3K改变局部结肠直肠癌.

Anna Martling1,2, Ida Hed Myrberg3, Mef Nilbert4

  • 1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.

The New England journal of medicine
|September 17, 2025
PubMed
概括
此摘要是机器生成的。

在患有PIK3CA突变的患者中,阿司匹林显著降低了结直肠癌复发率. 这一随机试验表明阿司匹林对这些特定癌症患者的无疾病生存有益.

更多相关视频

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

33.7K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

相关实验视频

Last Updated: Jan 17, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.4K
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
05:32

Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection

Published on: September 21, 2015

33.7K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

科学领域:

  • 在瘤学瘤学.
  • 遗传学 是一个遗传学.
  • 临床试验 临床试验

背景情况:

  • 阿司匹林使用与减少结直肠癌发病率有关.
  • 观察性研究表明,阿司匹林可以改善PIK3CA突变瘤患者的生存率.
  • 需要随机试验数据来确认这些好处.

研究的目的:

  • 评估阿司匹林在预防结肠直肠癌复发中的有效性.
  • 评估阿司匹林对患有PIK3K通路基因变异的患者无疾病生存的影响.
  • 确定阿司匹林在这个患者群体中的安全性.

主要方法:

  • 进行了一项双盲,随机,安慰剂对照试验.
  • 包括患有II/III期结肠癌或I-III期直肠癌以及PI3K通路基因变异的患者.
  • 参与者接受阿司匹林 (每天160毫克) 或安慰剂3年,根据PIK3CA突变状态分层.

主要成果:

  • 在患有PIK3CA热点突变的患者中,阿司匹林显著降低了3年复发发病率 (7.7%vs14.1%) 和其他PI3K路径改变 (7.7%vs16.8%).
  • 在两组中,阿司匹林改善了3年的无疾病生存率.
  • 与安慰剂 (11.6%) 相比,阿司匹林组 (16.8%) 的严重不良事件更频繁.

结论:

  • 在患有PIK3CA热点突变的患者中,阿司匹林显著降低了结直肠癌复发率.
  • 在其他体质PI3K通路基因变异的患者中也观察到类似的益处.
  • 这些发现支持阿司匹林在改善特定结肠直肠癌患者亚组的结果中的作用.